Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- 1 January 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 51 (1), 141-147
- https://doi.org/10.1161/hypertensionaha.107.096552
Abstract
Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with angiotensin-converting enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor–associated angioedema. Fifty subjects with a history of angiotensin-converting enzyme inhibitor–associated angioedema and 176 angiotensin-converting enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for angiotensin-converting enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with angiotensin-converting enzyme inhibitor–associated angioedema compared with angiotensin-converting enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during angiotensin-converting enzyme inhibition but not in the absence of angiotensin-converting enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during angiotensin-converting enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.Keywords
This publication has 44 references indexed in Scilit:
- Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edemaJournal of Allergy and Clinical Immunology, 2007
- A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme InhibitorsAmerican Journal of Human Genetics, 2005
- An evaluation of risk factors for adverse drug events associated with angiotensin‐converting enzyme inhibitorsJournal of Evaluation in Clinical Practice, 2004
- Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activityBrazilian Journal of Medical and Biological Research, 2003
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-BradykininJournal of Pharmacology and Experimental Therapeutics, 2002
- Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patientsAnnals of Allergy, Asthma & Immunology, 1999
- Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) geneImmunogenetics, 1994
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Bradykinin metabolism pathway in the rat pulmonary circulationJournal Of Hypertension, 1992